Table 1.

Reports in the literature of immunotherapy-associated renal adverse events and treatment

Author	No. of patients	Age	Gender	Medication	Cancer	Kidney biopsy	Treatment	Outcome
Fadel et al. [11] 2009	1	64	M	Ipilimumab	Melanoma	Extra-membranous and mesangial deposits of immunoglobulin (consistent with lupus nephritis)	Steroids	Resolved
Forde et al. [12] 2012	1	59	M	Ipilimumab	Melanoma	Not available	Steroids; no dialysis	Resolved
Voskens et al. [13] 2013	1	53	F	Ipilimumab	Mucosal	Not available	Steroids	Resolved
	2	72	F	Ipilimumab	Unknown primary	Not available	Steroids	Resolved
Izzedine et al. [14] 2014	1	72	M	Ipilimumab	Melanoma	Interstitial inflammation and poly-nuclear infiltration in glomerulus	Steroids	Resolved
	2	60	F	Ipilimumab	Melanoma	Tubulointerstitial inflammation with necrosis and two non-necrotizing granulomas	Steroids	Resolved
Thajudeen et al. [15] 2015	1	74	M	Ipilimumab	Melanoma	Interstitial edema with infiltrate of lymphocytes and granulomas	Steroids	Resolved; ipilimumab resumed
Vandiver et al. [16] 2016	1	58	F	Nivolumab	Melanoma	Not available	Steroids	Resolved
Hofmann et al. [17] 2016	1	52	M	Nivolumab	Melanoma	Not available	Steroids and normal saline	Resolved; nivolumab resumed
	2	73	M	Pembrolizumab	Melanoma	Not available	Steroids	Improved